Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Urothelial Bladder Carcinoma × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 108 Parkinson Disease 4, Autosomal Dominant Lewy Body 102 Melanoma 84 Neoplasms 60 Squamous Cell Carcinoma of Head and Neck 50 Colorectal Neoplasms 37 Triple Negative Breast Neoplasms 31 Lung Neoplasms 31 Carcinoma, Renal Cell 31 Breast Neoplasms 31 Urinary Bladder Neoplasms 29 Head and Neck Neoplasms 29 Neoplasm Metastasis 28 Stomach Neoplasms 27 Ovarian Neoplasms 26 Pancreatic Neoplasms 25 Carcinoma, Hepatocellular 25 Carcinoma, Transitional Cell 22 Recurrence 15 Endometrial Neoplasms 15 Sarcoma 13 Lymphoma 13 Esophageal Neoplasms 13 Carcinoma, Squamous Cell 12 Carcinoma 12 Uterine Cervical Neoplasms 11 Small Cell Lung Carcinoma 11 Prostatic Neoplasms 11 Fallopian Tube Neoplasms 11 Cholangiocarcinoma 11

Interventions

pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02736266 2023-07-18

PURE-01

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡